Clara Burtenshaw, Neo Kuma Ventures, on shattering the stigma of psychedelic medication

58:29
 
Share
 

Manage episode 296815175 series 2587257
By The Pulse by Wharton Digital Health. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
In this episode, we sat down with Clara Burtenshaw, Clara is a biotech and life sciences investor with significant transactional, VC, IP, and operational experience. We discussed: -The evolution of the psychedelics industry from a stigmatized counterculture phenomenon to a scientifically robust industry with support from the FDA for fast-tracking drug development -The clinical potential of psychedelics to treat illnesses ranging from mental illness to pain management and other nervous system disorders -Neo Kuma's focus on investing in early stage companies backed by sound science and building a strong founder network -Predictions that psychedelics as medication is here to stay, and the growing commercialization opportunities in the space

64 episodes